For the quarter ended March 2025, Becton Dickinson (BDX) reported revenue of $5.27 billion, up 4.5% over the same period last year. EPS came in at $3.35, compared to $3.17 in the year-ago quarter.

The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $5.37 billion. With the consensus EPS estimate being $3.28, the EPS surprise was +2.13%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- BD Life Sciences- Biosciences- United States: $142 million versus $145.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
• Revenues- BD Medical- Medication Delivery Solutions- United States: $687 million versus $703.87 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change.
• Revenues- BD Interventional- International: $384 million versus the four-analyst average estimate of $394.64 million. The reported number represents a year-over-year change of -2.8%.
• Revenues- BD Interventional- United States: $880 million versus the four-analyst average estimate of $913.82 million. The reported number represents a year-over-year change of -2%.
• Revenues- BD Interventional: $1.26 billion versus the five-analyst average estimate of $1.31 billion. The reported number represents a year-over-year change of -2.2%.
• Revenues- BD Interventional- Surgery: $383 million versus $393.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.1% change.
• Revenues- BD Interventional- Peripheral Intervention: $481 million versus $499.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
• Revenues- BD Interventional- Urology and Critical Care: $400 million versus $413.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change.
• Revenues- BD Medical- Advanced Patient Monitoring [$M]: $257 million versus the five-analyst average estimate of $261.87 million.
• Revenues- BD Medical: $2.76 billion versus the five-analyst average estimate of $2.77 billion. The reported number represents a year-over-year change of +12.7%.
• Revenues- BD Medical- Medication Delivery Solutions: $1.12 billion versus $1.15 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.
• Revenues- BD Life Sciences- Biosciences: $352 million compared to the $363.86 million average estimate based on five analysts. The reported number represents a change of -6.6% year over year.

View all Key Company Metrics for Becton Dickinson here>>>

Shares of Becton Dickinson have returned -8.5% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Becton, Dickinson and Company (BDX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research